US Patent

US10022447 — Solid pharmaceutical compositions containing pregabalin

Method of Use · Assigned to Warner Lambert Co LLC · Expires 2026-11-02 · 0y remaining

Vulnerability score 63/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a solid pharmaceutical composition containing pregabalin, suitable for once daily oral administration.

USPTO Abstract

A solid pharmaceutical composition containing pregabalin is described. The composition includes a matrix forming agent and a swelling agent and is suitable for once daily oral administration. Exemplary matrix forming agents include mixtures of polyvinyl acetate and polyvinylpyrrolidone, and exemplary swelling agents include cross-linked polymers of polyvinylpyrrolidone.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2137 — Lyrica
U-2137 — Lyrica
U-2137 — Lyrica

Patent Metadata

Patent number
US10022447
Jurisdiction
US
Classification
Method of Use
Expires
2026-11-02
Drug substance claim
No
Drug product claim
No
Assignee
Warner Lambert Co LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.